OW decisions
- 09/11/2023
- dabrafenib (Tafinlar®) plus trametinib (Mekinist®) for anaplastic thyroid cancer
-
-
-
Indication under consideration: the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation. This treatment will be limited to those patients whose tumour is deemed inoperable at the time of treatment commencement.
- 24/10/2023
- Test One Wales Page
-
-
- 20/10/2023
- sorafenib for acute myeloid leukaemia (AML) maintenance
-
-
-
Using the agreed starting and stopping criteria, sorafenib can be made available within NHS Wales for maintenance treatment following allogeneic stem cell transplantation for acute myeloid leukaemia associated with a FLT3 ITD mutation.
The risks and benefits of the off-label use of sorafenib for this indication should be clearly stated and discussed with the patient to allow informed consent.